Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder
Gilgamesh Pharmaceuticals received a $14M NIDA grant for GM-3009, a cardiac-safe ibogaine analog for opioid use disorder treatment, aiming to eliminate ibogaine's cardiovascular risks and prove efficacy in Phase 1/1b trials, marking a potential breakthrough in addiction therapy.
Reference News
Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder
Gilgamesh Pharmaceuticals received a $14M NIDA grant for GM-3009, a cardiac-safe ibogaine analog for opioid use disorder treatment, aiming to eliminate ibogaine's cardiovascular risks and prove efficacy in Phase 1/1b trials, marking a potential breakthrough in addiction therapy.